About erenumab AMG 334



Erenumab is designed to specifically block the CGRP receptor, which plays a critical role in migraine activation. It is being co-developed by Novartis and Amgen. 

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.

Request Access to Download

This file is for journalists only. Please fill out the form below to request access.

By submitting this field I verify that I am a journalist.